TNFα-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications

Arthritis and Rheumatism

Volumn 43, Issue 10, 2000, Pages 2368-2377

  Pachman, Lauren M ^a   Liotta Davis, Margaret R ^a   Hong, David K ^a   Randall Kinsella, T ^a   Mendez, Eduardo P ^a   Kinder, Jennifer M ^a   Chen, Edwin H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIFEDIOL; CALCITRIOL; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ALLELE; ARTICLE; CALCIFICATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MONONUCLEAR CELL; MUSCLE WEAKNESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; CLINICAL TRIAL; GENETICS; METABOLISM; MULTICENTER STUDY; PRESCHOOL CHILD;

ALLELES; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033623341     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8     Document Type: Article

References (78)

1. Dermatomyositis
2. Course of treated juvenile dermatomyositis
3. An update on juvenile dermatomyositis
4. Juvenile dermatomyositis at diagnosis: Clinical characteristics of 79 children
5. Juvenile dermatomyositis: Medical, social and economic status in adulthood
6. Juvenile dermatomyositis and polymyositis: A follow-up study of long-term sequela
7. Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis
8. Dermatomyositis in the pediatric patient
9. Childhood dermatomyositis: Clinical course and long term follow-up
10. Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens
11. Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies
12. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: Increased risk associated with HLA-DQA1*0501
13. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis
14. Immunogenetic studies in families of children with juvenile dermatomyositis
15. Polymorphic MHC ancestral haplotypes affect the activity of tumor necrosis factor-alpha
16. Genetics of tumor necrosis factor α in autoimmune, infectious, and neoplastic diseases
17. At diagnosis, African American children with juvenile dermatomyositis may have a different presentation than Caucasian or Hispanic children: Physician reported data from NIAMS juvenile DM Research Registry
18. Increased neopterin levels in juvenile dermatomyositis correlate with disease activity and are indicative of macrophage activation
19. Correlations of serum neopterin concentrations with disease activity in juvenile dermatomyositis
20. Flow cytometric analysis of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis
21. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis
22. Determination of the von Willebrand's disease antigen (factor VIII related antigen) in plasma by quantitative immunoelectrophoresis
23. Activation of complement and coagulation in juvenile dermatomyositis
24. Sequential studies of neopterin, von Willebrand factor antigen creatine kinase and aldolase in juvenile dermatomyositis: Correlates of disease activity?
25. Von Willebrand factor in juvenile dermatomyosifis
26. MRI directed muscle biopsy for assessment of juvenile dermatomyositis response to therapy: Comparison of initial and follow-up biopsies using a histological rating scale evaluating disease severity/chronicity
27. Predictive value of nailfold capillary studies in the diagnosis of connective tissue diseases
28. Ficoll-Hypaque method for separating mononuclear cells and granulocytes from human blood
29. A rapid and simple method of measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
30. A novel assay for apoptosis: Flow cytometric detection of phosphatidyl-serine expression of early apoptotic cells using fluorescein labeled annexin V
31. Secretion of tumor necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF gene and HLA-DR alleles: Relevance of inflammatory bowel disease
32. Single base polymorphism in the human tumor necrosis factor (TNFα) gene detected by NcoI restriction of PCR product
33. Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the RO (SS-A)/La (SS-B) autoantibody responses
34. Classification and treatment of the juvenile idiopathic inflammatory myopathies
35. Interethnic differences in the association of tumor necrosis factor promoter polymorphisms with systemic lupus erythematosus
36. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis
37. Peripheral blood mononuclear cells from children with active juvenile dermatomyositis produce endogenous TNF-α
38. Tumor necrosis alpha (TNFα) allelic polymorphisms at position - 308: Association of the TNF2 allele with chronic disease course and increased endogenous in vitro production of TNFα by unstimulated mononuclear cells (PBMCs) from children with juvenile dermatomyositis (juvenile DM)
39. The incidence of juvenile dermatomyositis: Results from a nation-wide study
40. The TNFA2 allele (AA, GA) is associated with calcinosis, a chronic disease course, and increased in vitro production of TNF-α, but not TGF-β by peripheral blood mononuclear cells from children with juvenile dermatomyositis
41. The incidence of juvenile dermatomyositis: Results from the NIAMS juvenile DM Research Registry
42. Clinical significance of specific autoantibodies in juvenile dermatomyositis
43. HLA-B8 in juvenile dermatomyositis
44. An allelic polymorphism within the human tumor necrosis factor α promoter region is strongly associated with HLA1, B8, and DR3 alleles
45. A polymorphic variation in a putative regulation box of the TNF-α promoter region
46. Tumor necrosis factor alpha gene polymorphisms and rheumatic diseases
47. Sequence analysis of the tumor necrosis factor gene in pediatric patients with autoimmunity
48. Relevance of the tumor necrosis factor alpha (TNFα) -308 promoter polymorphism in the TNFα gene regulation
49. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription
50. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
51. Differential expression of HLA-DQA1 alleles associated with promoter polymorphism
52. Variations in the TNF-α promoter region associated with susceptibility to cerebral malaria
53. Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy
54. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis
55. Polymorphisms within the human tumor necrosis factor-alpha promoter region in human immunodeficiency virus type 1-seropositive persons
56. Tumor necrosis factor microsatellites show association with multiple sclerosis
57. Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis
58. Association of polymorphisms within the tumor necrosis factor (TNF) genes and childhood asthma
59. Tumor necrosis factor microsatellite haplotypes are different in male and female patients with RA
60. New-onset juvenile dermatomyositis: Comparisons with a healthy cohort and children with juvenile rheumatoid arthritis
61. Parent report of antecedent illness and environmental factors before onset of juvenile dermatomyositis in children: NIAMS juvenile DM Research Registry data
62. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis
63. Identification of cross-reactive epitopes on human skeletal myosin and streptococcal M5 protein in patients with juvenile dermatomyositis
64. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus
65. Association between HLA-DR2 and production of tumor necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide
66. Tumor necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans
67. TNF-α -308 polymorphism (AA, GA) is associated with increased UVB induced keratinocyte TNF-a production in-vitro
68. Juvenile dermatomyositis presenting with rash alone
69. ++) with intermittent high-dose intravenous methylprednisolone (IV pulse) therapy
70. Imperfect indications of disease activity in juvenile dermatomyositis
71. Relationship of von Willebrand factor antigen to disease activity in juvenile dermatomyositis
72. Comprehensive rehabilitative management of patients with polymyositis and dermatomyositis
73. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis
74. An update on juvenile dermatomyositis
75. Previous antibiotic adverse reactions are a risk factor for adverse reactions to pulse intravenous corticosteroids (PIVCS) in children
76. A comparison of the cost effectiveness of IV and PO corticosteroids in the treatment of juvenile dermatomyositis
77. Genomic characterization of the region between HLA-B and TNF: Implications for the evolution of multicopy gene families